Viatris Adds Non-Opioid Pain Business With Approximately $1.69 Billion Pacira Purchase
Viatris expects Pacira to contribute $90 million to $100 million in revenue for the remainder of 2026.
Viatris, which supplies generic, brand-name and innovative medicines worldwide, completed its approximately $1.69 billion purchase of Pacira BioSciences on Tuesday. The deal brings the non-opioid pain-management company into Viatris as it expands its U.S. innovative medicines business, according to its SEC filing and accompanying company release.
Pain Medicines Join A Global Portfolio
Viatris expects Pacira to generate $90 million to $100 million in revenue for the rest of 2026, covering November 17 through December 31. That forecast gives investors a first measure of the business's expected contribution now that the acquisition is complete.
Scott A. Smith, Viatris' CEO, said the deal advances its strategy to "strengthen our U.S. innovative medicines business." Smith said he aims to establish a leading position in non-opioid pain management and accelerate sustained growth in revenue and earnings.
Viatris' existing portfolio includes complex generics and established branded drugs alongside its expanding innovative-medicines business. The company reported $14.30 billion in total revenue in 2025 and operates across Developed Markets, Emerging Markets, JANZ and Greater China.
Its medicines reach patients through pharmacies, retailers, wholesalers, governments, institutions and physicians. Its global footprint spans more than 165 countries and territories, with more than 30,000 employees and 27 sites for manufacturing, packaging and distribution.
Cash Terms For Pacira Holders
Pacira shareholders receive $36.50 per share in cash under the offer. The approximately $1.69 billion total excludes transaction fees and expenses, and Viatris will pay for the purchase using available cash and short-term borrowing.
Viatris signed the merger agreement on October 8, 2026, and launched the offer to buy shareholders' stock on October 30. The offer and the right to withdraw tendered shares expired one minute after 11:59 p.m. Eastern Time on Monday.
Shareholders tendered 32,929,780 shares without withdrawing them, representing approximately 66.46% of Pacira's outstanding stock. That participation allowed the merger to proceed without a Pacira shareholder vote.
Pacira is now wholly owned by Viatris. Shares that were not tendered generally became rights to receive the same cash price; holders who properly exercised appraisal rights are subject to the separate appraisal process.
Pacira shares will be delisted from the Nasdaq Global Select Market as a result of the completed acquisition.
Sources
- 8-K Filing — Viatris Inc (VTRS) — SEC EDGAR
- Exhibit ef20085674_ex99-1.htm — Viatris Inc 8-K exhibit — SEC EDGAR
- Viatris Completes Acquisition of Pacira BioSciences — prnewswire.com